Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Oct 25 - Oct 30
A randomized, double-blind, controlled phase II trial in advanced renal cell carcinoma (RCC) demonstrated synergistic anticancer effects with the combination of the glutaminase inhibitor telaglenastat (CB-839) and the mTOR inhibitor everolimus (TelaE), which was well tolerated by patients previously treated with TKIs
[DOI] [PubMed] [Google Scholar] 62.Klomsiri C, Karplus PA, Poole LB
Serum isolation and ALT activity quantification Collected blood samples were placed in 1.5 mL centrifuge tubes that were subsequently submitted to overnight incubation at 4 C and allowed to clot
Maffioletti, E., Zanardini, R., Gennarelli, M
NADH .[12]
US$ 22.22
US$ 27.67
US$ 27.48
